CureVac (NASDAQ:CVAC - Get Free Report) issued its quarterly earnings data on Thursday, April 10th. The company reported ($0.15) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.01), Zacks reports. CureVac had a return on equity of 21.98% and a net margin of 20.72%. The firm had revenue of $15.44 million during the quarter, compared to analyst estimates of $6.40 million.
CureVac Stock Performance
CVAC traded down $0.08 during trading hours on Thursday, hitting $3.12. 282,787 shares of the stock were exchanged, compared to its average volume of 809,781. The company has a debt-to-equity ratio of 0.05, a current ratio of 6.20 and a quick ratio of 6.19. CureVac has a 12 month low of $2.22 and a 12 month high of $5.28. The stock has a 50-day simple moving average of $3.10 and a 200-day simple moving average of $3.16. The stock has a market cap of $698.51 million, a price-to-earnings ratio of 5.67 and a beta of 2.48.
Wall Street Analysts Forecast Growth
Separately, JMP Securities reaffirmed a "market outperform" rating and issued a $16.00 target price on shares of CureVac in a research report on Friday, February 14th.
Read Our Latest Report on CureVac
CureVac Company Profile
(
Get Free Report)
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.
Featured Stories
Before you consider CureVac, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CureVac wasn't on the list.
While CureVac currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
